On Monday (August 19), PharmaCielo (TSXV:PCLO,OTC Pink:PHCEF) confirmed that it has completed its first shipment of cannabidiol (CBD) isolate to Switzerland.

The shipment of CBD, which is used in health and lifestyle products, was sent to the Swiss headquarters of Creso Pharma (ASX:CPH), an Australia-based cannabis company that PharmaCielo acquired in June.

“PharmaCielo is the first medicinal cannabis company to commercially export cannabis derived isolates from Colombia to Switzerland — the global capital of the pharma industry,” said PharmaCielo CEO David Attard in a press release.


Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!

The news comes after the company secured its first commercial exporting permit from the Colombian government last month.

Attard added that the company’s ability to successfully export cannabis products has given it an advantage in the European market.

Cannabis is currently illegal in Switzerland, but products derived from cannabis plants with low tetrahydrocannabinol (THC) levels (less than 1 percent) can be sold legally. In 2012, the possession of 10 grams of cannabis or less was decriminalized and is no longer a criminal infringement; however, it is still punishable by a fine of 100 Swiss francs.

As for medical marijuana, there is only one product — Sativex, generically known as Nabiximols — licensed for sale in the European country. Otherwise, the Federal Office of Public Health (FOPH) can grant special authorization for the medical use of prohibited narcotics, including cannabis.

Medical marijuana in the country may be legalized in the near future though. A proposal from the Swiss government released earlier this year aims to allow prescriptions for cannabis to treat people suffering from cancer and other conditions.

The proposal would replace the existing system, which involves getting an exception from the FOPH; it could further open up Switzerland’s cannabis market.

PharmaCielo’s collaboration with Creso Pharma also involves a multi-country agreement with Uruguay-based Laboratorios Adler, which was announced last week.

As part of the deal, PharmaCielo will supply the Latin American company, a veterinary product producer, with its CBD products and Creso Pharma’s veterinarian CBD products for distribution in Uruguay, Paraguay, Bolivia and Southern Brazil.

As part of PharmaCielo’s results for Q1 2019, the company reported that is in “active negotiations” across multiple markets in South America and the European Union.

According to those results, the company’s operating costs reached C$4.8 million during the period, a drop from C$9.6 million in the same quarter last year.

PharmaCielo also reported a drop in its total net loss, which fell from C$10 million during the same quarter in 2018 to C$7.7 million in Q1 of this year.

The company’s share price has jumped since the announcement, rising to C$5.64 by 10:20 a.m. EDT on Monday; that represents an almost 5 percent increase from Friday’s (August 16) close of C$5.37. As of 3:00 p.m. EDT on Monday, shares of the company were trading at a price of C$5.50.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Danielle Edwards, hold no direct investment interest in any company mentioned in this article.


Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!

Appointment of Dr. Kelmendi, Assistant Professor of Psychiatry at Yale University and co-founder of the Yale Psychedelic Science Group, brings another experienced medical professional to Lobe’s advisory team.

 Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce the appointment of Benjamin Kelmendi, MD, Assistant Professor of Psychiatry at Yale University School of Medicine, to its Scientific Advisory Board.

Keep reading... Show less

Ayurcann Holdings Corp. ( CSE: AYUR ) (the “ Company ” or ” Ayurcann “), a Canadian extraction company specializing in the processing of cannabis and hemp for the production of oils and various derivative products, is pleased to unveil further details of its Phase 2 expansion plans.

Ayurcann has commenced trading on the Canadian Securities Exchange (” CSE “) on April 8, 2021 and subsequently announced a private placement of up to $500,000 (” Financing “), as per the Company’s press release dated April 12, 2021. The proceeds of the Financing are intended to be used to further pursue Phase 2 of the expansion of the production capacity of the Company’s Pickering facility.

Keep reading... Show less

New findings suggest the COVID-19 pandemic, combined with expanded state legalization, has attracted new consumers to the category and accelerated cannabis acceptance and adoption.

  • YouGov study indicates the number of current cannabis consumers has increased 56% within just two years compared to the 16% of Americans who reported current consumption in 2018.
  • 23% of current consumers say they tried cannabis for the first time within the past year.
  • More than half of cannabis consumers say they will purchase or try a new product or format this 420, indicating that the holiday is becoming increasingly focused on exploration and trial.

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco Labs” or the “Company”), a vertically integrated multistate operator and the number one U.S. wholesaler of branded cannabis products, released the results of a survey today showing one in four Americans currently consume cannabis, reporting they’ve tried some form of cannabis within the past twelve months. That’s a significant increase since 2018* when just 16% of U.S. adults reported current consumption, representing a 56% increase in just two years. What’s more, 23% of current cannabis consumers say they tried cannabis for the first time over the past year, suggesting the COVID-19 pandemic, combined with expanded state legalization, has rapidly accelerated cannabis acceptance and adoption in America.

Keep reading... Show less

Acquires Three Operating Dispensaries in Northeast Pennsylvania

Purchase price represents a mid-single digit multiple of KCR’s expected 2021 EBITDA

Keep reading... Show less

TransCanna Holdings Inc. (CSE: TCAN) (FSE: TH8) (“TransCanna” or the “Company”) subsidiary Lyfted Farms has much to commemorate this 420 (April 20th) known as the international day of celebration and celebratory consumption of cannabis.

The Company fulfilled an impressive $100k initial order of 25 pounds of premium indoor exotic cannabis flower and concentrates that hit the shelves of 14 famed STIIIZY retail locations throughout California last week, just ahead of the biggest day in cannabis counterculture.

Keep reading... Show less